OOIR: Observatory of International Research

Papers

(The H4-Index of Expert Opinion on Drug Safety is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Adverse event profiles of drug-induced decreased libido: an assessment of the US food and drug administration Adverse Event Reporting System	130
An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder	122
Novel insights into post-marketing AEs associated with bempedoic acid: a comprehensive analysis utilizing the FAERS database	96
Adverse events in patients with cardiovascular disease taking proton pump inhibitors	45
Comparison of adverse events of poly adenosine diphosphate ribose polymerase inhibitors in patients with ovarian cancer using the United States Food and Drug Administration Adverse Event Reporting Sys	45
Safety concerns associated with various types of statins: a disproportionality analysis of the FAERS database	42
The role of artificial intelligence in pharmacovigilance for rare diseases	39
Safety assessment of brexanolone in the FAERS database: real adverse event analysis and discussion of side effects	38
Safety profile of isocitrate dehydrogenase inhibitors in cancer therapy: a pharmacovigilance study of the FDA Adverse Event Reporting System	35
Exploration of cardiac adverse events associated with relugolix and degarelix: a multi-center pharmacovigilance study based on the FAERS database	34
A real-world pharmacovigilance study of QT interval prolongation and Torsades de Pointes associated with CDK4/6 inhibitors in breast cancer patients: findings from the FDA adverse event reporting syst	34
An updated safety review of Hidradenitis Suppurativa treatment options	33
Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment	31
Drug-induced hepatitis B virus reactivation: insights from FAERS database analysis	27
The safety of phthalate-containing medications used during pregnancy	27
Why is pharmacovigilance essential for biosimilars?	26
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 monoclonal antibodies: a systematic review and meta-analysis of observational studies	26
Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile	24
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis	24
Assessment of adverse events related to anti-interleukin-6 receptor monoclonal antibodies using the FDA adverse event reporting system: a real-world pharmacovigilance study	24
Exploration and evaluation of adverse event signals of droxidopa based on the FAERS database	24
Assessment of adverse events of the novel antiepileptic drug lamotrigine: a real-world pharmacovigilance study based on FAERS	23
The effectiveness and safety of aripiprazole, bromocriptine, and cabergoline in the treatment of hyperprolactinemia: a systematic review and network meta-analysis	22
Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database	22
Safety and efficacy of anti-SARS-CoV-2 monoclonal antibodies in pregnancy	22